June 1, 2026 – Type 1 Diabetes TrialNet (TrialNet), the world’s leading international research network dedicated to the prevention of type 1 diabetes, today announced the appointment of Michael Haller, MD, as Chair and Carmella Evans-Molina, MD, PhD, as Vice Chair.

Dr. Haller, Chief of Pediatric Endocrinology at the University of Florida, succeeds Kevan Herold, MD, of the Yale School of Medicine. Dr. Evans-Molina, Director of the Center for Diabetes and Metabolic Diseases at Indiana University (IU) School of Medicine, succeeds Linda DiMeglio, MD, MPH, also of IU School of Medicine.

The appointments follow significant achievements under the previous leaders, including FDA approval of the first drug (teplizumab) to delay the onset of type 1 diabetes and surpassing the milestone of screening 250,000 individuals for type 1 diabetes risk.

“We are at a historic turning point,” says Dr. Haller. “After decades of proving that we can modify the pathway of type 1 diabetes, we are shifting our focus to identifying treatments more quickly. We will accomplish this through increased efficiencies and novel study designs at every stage of the disease.”

Dr. Evans-Molina, recognized for her research on pancreatic beta-cell destruction, will collaborate closely with Dr. Haller to implement new initiatives while leveraging the network’s extensive pool of talent.

Dr. Haller and Dr. Evans-Molina are eager to build on the current momentum as TrialNet launches a pipeline of new clinical studies and advances the important work initiated by previous leaders.

“We recognize and extend our gratitude to Dr. Herold, Dr. DiMeglio, and past TrialNet leadership,” said Dr. Evans-Molina. “Due to their efforts and our exceptional network, TrialNet is the premier destination for conducting type 1 diabetes clinical trials.”

About TrialNet
TrialNet (NCT00097292), the largest clinical trial network ever assembled to change the course of type 1 diabetes, is funded by the National Institutes of Health (NIH), primarily through the Special Statutory Funding Program for Type 1 Diabetes. TrialNet data collected from more than 250,000 relatives of people with type 1 diabetes over 20 years led to the development of the stages of type 1 diabetes, making it possible to identify who will develop the disease and advancing prevention research. TrialNet offers free risk screening for relatives of people with type 1 diabetes and innovative clinical studies testing ways to delay and prevent disease progression. Learn more at www.trialnet.org.